TrialBMC cancer2012

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).

Christos Chouaid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.